drugset / Trial / NCT01209832
A Tasisulam and Midazolam Drug Interaction Study in Cancer Patients
NaSingle-groupOpen-labelBasic science
Summary
The purpose of this study is to evaluate whether tasisulam acts as an inducer of CYP3A using midazolam as a sensitive and specific probe substrate of CYP3A. The study will also assess the safety and tolerability of tasisulam and midazolam given in combination and document any antitumor activity with tasisulam.
Timeline
- Start
- 2010-09
- Primary completion
- 2011-01
- Completion
- 2011-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Midazolam | Small molecule | 1.2 mg | Oral |
| Subject | Tasisulam | Small molecule | — | Intravenous |